MedTrace Logo

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

NCT03986073 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-03-13

No results posted yet for this study

Summary

TQ-F3083 capsule is a new type inhibitor of DPP-IV, which is currently a very effective target for the treatment of type 2 diabetes mellitus at clinical. In addition, it can promote insulin secretion with low potential toxicity, and half-life is shorter than Linagliptin.

Conditions

Interventions

DRUG

TQ-F3083 capsule 10 mg

Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.

DRUG

TQ-F3083 capsule 20 mg

Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.

DRUG

TQ-F3083 blank analog capsule

Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.

DRUG

TQ-F3083 blank analog capsule

Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.

DRUG

Linagliptin blank analog tablet

Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.

DRUG

Linagliptin tablet

Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-06-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986073 on ClinicalTrials.gov